Using Artificial Intelligence to predict ERG Gene Fusion in Prostate Cancer

The role of artificial intelligence (AI) in healthcare continues to expand. In a recent issue of BMC Cancer, Dr. Vipulkumar Dadhania (first author) and colleagues published a result of their study Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. The expert team from the Michigan Center for Translational Pathology developed a deep-learning-based model to predict ERG genomic rearrangements in prostatic adenocarcinomas using only H&E-stained digital slides. Their AI models were accurate at 78.6%-79.7%, depending on the magnification, with a 20x magnification the most accurate. Sensitivity was found to be at 75% across magnification levels (10x, 20x, 40x) and specificity ranged from 81.7% (10x and 40x) to 83.1% (20x).